Company: LCTX
Filing Date: 2025-07-02
Form Type: 8-K
Source: 0000950170-25-093007
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-07-02
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As described under Item 5.07 below, at the annual meeting of shareholders (the “ Annual Meeting”) of Lineage Cell Therapeutics, Inc. (the “ Company”) held on June 26, 2025, the Company’s shareholders approved an amendment (the “ EIP Amendment”) to the Company’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”), pursuant to which the number of common shares of the Company available for issuance under the 2021 Plan was increased by 19,500,000. The Company’s board of directors (the “ Board”) previously approved the EIP Amendment, subject to shareholder approval. A more complete description of the EIP Amendment and a summary of the 2021 Plan, as amended by the EIP Amendment, is in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the U. S. Securities and Exchange Commission on April 29, 2025 (the “ Proxy Statement”), and is incorporated herein by reference. The foregoing summary of the EIP Amendment is qualified in its entirety by reference to the EIP Amendment, a copy of which is filed as an exhibit to this report.